BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tomimaru Y, Aihara A, Wands JR, Aloman C, Kim M. A Novel Drug, CC-122, Inhibits Tumor Growth in Hepatocellular Carcinoma through Downregulation of an Oncogenic TCF-4 Isoform. Transl Oncol 2019;12:1345-56. [PMID: 31352197 DOI: 10.1016/j.tranon.2019.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Cheng Y, Chen J, Pourdehnad M, Zhou S, Li Y. Population Pharmacokinetics of CC-122. Clin Pharmacol 2021;13:61-71. [PMID: 33958900 DOI: 10.2147/CPAA.S310604] [Reference Citation Analysis]
2 Tu W, Gong J, Song J, Tian D, Wang Z. miR-20a/TCF4 axis-mediated inhibition of hepatocytes proliferation impairs liver regeneration in mice PHx model by regulating CDC2 and CDC6. J Cell Mol Med 2021;25:5220-37. [PMID: 33951279 DOI: 10.1111/jcmm.16530] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Li Y, MacGorman K, Liu L, Chen J, Hoffmann M, Palmisano M, Zhou S. Single-Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC-122) in Subjects With Mild, Moderate, or Severe Renal Impairment. Clin Pharmacol Drug Dev 2020;9:785-96. [PMID: 31891240 DOI: 10.1002/cpdd.760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]